SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma informs about the press releaseinforms about the press release

16 Aug 2022 Evaluate

Aurobindo Pharma has informed that it enclosed a copy of the Press Release that is being issued by the Company in connection with USFDA approval received by Eugia Pharma Specialities, a wholly owned subsidiary of the Company, for Vasopressin Injection USP.

The above information is a part of company’s filings submitted to BSE.


Aurobindo Pharma Share Price

1371.20 -14.45 (-1.04%)
20-Apr-2026 14:29 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1670.85
Dr. Reddys Lab 1236.40
Cipla 1233.10
Zydus Lifesciences 937.40
Lupin 2329.40
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×